Management of agitation and aggression associated with Alzheimer disease (Q37504709)

20 August 2017

1 reference

title

Management of agitation and aggression associated with Alzheimer disease (English)

1 reference

20 August 2017

0 references

3

Jeffrey L Cummings

1 reference

20 August 2017

4

Henry Brodaty

1 reference

20 August 2017

Constantine G. Lyketsos

series ordinal

7

object named as

Constantine G Lyketsos

1 reference

20 August 2017

5

George T Grossberg

1 reference

20 August 2017

Clive G Ballard

1

1 reference

20 August 2017

Serge Gauthier

series ordinal

2

1 reference

20 August 2017

Philippe Robert

series ordinal

6

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

Nature Reviews Neurology

1 reference

20 August 2017

5

1 reference

20 August 2017

5

1 reference

20 August 2017

245-255

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2009.39

20 August 2017

0 references

cites work

A follow up study of depression in the carers of dementia sufferers.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A metaanalysis of controlled trials of neuroleptic treatment in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Treatment of agitation in AD: a randomized, placebo-controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A randomized trial of dementia care in nursing homes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Aromatherapy as a Safe and Effective Treatment for the Management of Agitation in Severe Dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy and tolerability of carbamazepine for agitation and aggression in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Clinical management of dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Behavioral problems in dementia: a factor analysis of the neuropsychiatric inventory.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients'

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Antipsychotic prescribing patterns in care homes and relationship with dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Neuroleptic drugs in dementia: benefits and harm

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: a controlled, double-blind study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Withdrawal of neuroleptic medications from institutionalized dementia patients: results of a double-blind, baseline-treatment-controlled pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A 3-Month, Randomized, Placebo-Controlled, Neuroleptic Discontinuation Study in 100 People With Dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Melatonin and bright-light treatment for rest-activity disruption in institutionalized patients with Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviours in Chinese older persons with dementia: a cross-over randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Sensory stimulation in dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease.

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

31 March 2020

12 December 2020

Effects of donepezil on neuropsychiatric symptoms in patients with dementia and severe behavioral disorders

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Donepezil for the treatment of agitation in Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Evaluation of the impact of memantine treatment initiation on psychotropics use: a study from the French national health care database.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Design of Depression in Alzheimer's Disease Study-2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Mood stabilizers in Alzheimer's disease: symptomatic and neuroprotective rationales

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

A placebo-controlled trial of valproate for agitation and aggression in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

5-HT2A and 5-HT2C receptor polymorphisms and psychopathology in late onset Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Role of serotonin transporter polymorphisms in the behavioural and psychological symptoms in probable Alzheimer disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

The 5-HTTPR polymorphism confers liability to a combined phenotype of psychotic and aggressive behavior in Alzheimer disease

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

31 March 2020

12 December 2020

Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Neuropathological correlates of psychotic phenomena in confirmed Alzheimer's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

An evidence-based proposal for the classification of neuropsychiatric disturbance in Alzheimer's disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2009.39

Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: the results of a double-blind, placebo-controlled trial with Melissa.

31 March 2020

1 reference

12 December 2020

Validation therapy for dementia

1 reference

12 December 2020

Memantine for dementia

1 reference

12 December 2020

Neuroleptic Drugs in the Management of Behavioral Symptoms of Alzheimer’s Disease

1 reference

12 December 2020

Aroma therapy for dementia

1 reference

12 December 2020

For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not?

1 reference

12 December 2020

Haloperidol for agitation in dementia.

1 reference

12 December 2020

Valproate preparations for agitation in dementia

1 reference

12 December 2020

Galantamine for Alzheimer's disease and mild cognitive impairment

1 reference

12 December 2020

The impact of dementia on the family

1 reference

12 December 2020

A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

1 reference

12 December 2020

A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia

1 reference

12 December 2020

Effect of light on agitation in institutionalized patients with severe Alzheimer disease

1 reference

12 December 2020

A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease

1 reference

12 December 2020

Trazodone for agitation in dementia

1 reference

12 December 2020

Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies

1 reference

12 December 2020

Donepezil for dementia due to Alzheimer's disease

1 reference

12 December 2020

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial

1 reference

12 December 2020

Rivastigmine for Alzheimer's disease.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEUROL.2009.39

1 reference

Dimensions Publication ID

20 August 2017

0 references

1 reference